MCID: PPL001
MIFTS: 44

Papillary Adenoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Papillary Adenoma

MalaCards integrated aliases for Papillary Adenoma:

Name: Papillary Adenoma 12 15 71
Glandular Papilloma 12 71
Adenoma 43 71

Classifications:



External Ids:

Disease Ontology 12 DOID:3172
MeSH 43 D000236
NCIt 49 C79951
SNOMED-CT 67 86143001
UMLS 71 C0001430 C0205650 C3282896

Summaries for Papillary Adenoma

MalaCards based summary : Papillary Adenoma, also known as glandular papilloma, is related to wolffian duct adenoma and nephrogenic adenoma of urinary bladder. An important gene associated with Papillary Adenoma is KRT7 (Keratin 7), and among its related pathways/superpathways are MicroRNAs in cancer and ErbB signaling pathway. The drugs Linaclotide and Dyclonine have been mentioned in the context of this disorder. Affiliated tissues include colon, pituitary and testes, and related phenotypes are neoplasm and normal

Related Diseases for Papillary Adenoma

Diseases related to Papillary Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1960)
# Related Disease Score Top Affiliating Genes
1 wolffian duct adenoma 34.4 KRT7 AMACR
2 nephrogenic adenoma of urinary bladder 34.0 KRT7 AMACR
3 apocrine adenoma 34.0 KRT7 KRAS
4 urinary bladder villous adenoma 33.8 KRT7 CEACAM5
5 urethral villous adenoma 33.8 KRT7 CEACAM5
6 nephrogenic adenoma of the urethra 33.7 KRT7 KRT5 AMACR
7 periampullary adenoma 33.7 KRAS HRAS
8 ceruminoma 33.6 KRT7 KRT5
9 middle ear adenoma 33.5 SYP KRT7 KRT5
10 renal adenoma 33.5 TFE3 PRCC KRT7 AMACR
11 colorectal adenoma 33.5 TP53 KRAS HRAS
12 pleomorphic adenoma 33.4 VIM TP53 KRT7 HRAS
13 vaginal adenoma 33.4 SYP KRT7
14 vaginal tubulovillous adenoma 33.3 SYP KRT7 KRAS CEACAM5
15 chromophil adenoma of the kidney 32.6 TFE3 PRCC KRT7 AMACR
16 lung adenoma 32.4 TP53 SFTPC SCGB1A1 KRAS HRAS
17 myh-associated polyposis 32.3 KRAS HRAS
18 eccrine acrospiroma 32.1 KRT7 KRT5 CEACAM5
19 epithelial-myoepithelial carcinoma 32.1 VIM TP53 KRT7 HRAS
20 endometrial adenocarcinoma 32.0 VIM TP53 KRT7 KRAS
21 appendix adenocarcinoma 31.2 SYP KRT7 KRAS HRAS CEACAM5
22 secretory meningioma 31.0 VIM KRT7 CEACAM5
23 subareolar duct papillomatosis 30.9 KRT7 KRT5
24 adenoma 30.9 TP53 SYP KRT7 KRAS
25 urethral diverticulum 30.8 KRT7 AMACR
26 warthin tumor 30.6 KRT7 CEACAM5
27 syringoma 30.5 VIM KRT7 CEACAM5
28 cystitis 30.4 VIM TP53 KRT7
29 fibroma 30.4 VIM KRT7 KRAS
30 thyroid carcinoma, familial medullary 30.3 NKX2-1 KRAS CEACAM5
31 neuroendocrine tumor 30.3 SYP NKX2-1 HRAS
32 hyperplastic polyposis syndrome 30.3 TP53 KRAS
33 nephrogenic adenofibroma 30.3 TFE3 KRT7
34 alveoli adenoma 30.2 SFTPC SCGB1A1 NKX2-1
35 papillary carcinoma 30.2 SYP NKX2-1 KRT7
36 myoepithelial carcinoma 30.2 VIM TP53 KRT7 HRAS
37 lynch syndrome 30.2 TP53 OGG1 KRAS HRAS
38 pulmonary sclerosing hemangioma 30.2 SYP NKX2-1 KRT7
39 tubular adenocarcinoma 30.2 SYP KRT7 CEACAM5
40 adrenal cortical carcinoma 30.2 VIM TP53 SYP
41 chordoma 30.2 VIM TP53 KRT7
42 struma ovarii 30.2 NKX2-1 KRT7 KRAS
43 anal paget's disease 30.2 KRT7 CEACAM5
44 ceruminous adenocarcinoma 30.1 KRT7 KRT5
45 thyroid tumor 30.1 TP53 KRAS HRAS
46 olfactory neuroblastoma 30.1 VIM SYP NKX2-1
47 angiomyolipoma 30.1 VIM TFE3 KRT7
48 rectum cancer 30.1 KRAS HRAS CEACAM5
49 urachal adenocarcinoma 30.1 KRAS CEACAM5
50 spiradenoma 30.1 VIM TP53 KRT7

Graphical network of the top 20 diseases related to Papillary Adenoma:



Diseases related to Papillary Adenoma

Symptoms & Phenotypes for Papillary Adenoma

MGI Mouse Phenotypes related to Papillary Adenoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.7 HRAS KRAS NKX2-1 OGG1 SCGB1A1 SFTPC
2 normal MP:0002873 9.56 HRAS KRAS NKX2-1 OGG1 SCGB1A1 SYP
3 respiratory system MP:0005388 9.17 HRAS KRAS NKX2-1 SCGB1A1 SFTPC TP53

Drugs & Therapeutics for Papillary Adenoma

Drugs for Papillary Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 424)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Linaclotide Approved Phase 4 851199-59-2 65351
2
Dyclonine Approved Phase 4 586-60-7 3180
3
Scopolamine Approved, Investigational Phase 4 6533-68-2, 51-34-3 5184
4
Pantoprazole Approved Phase 4 102625-70-7 4679
5
Clarithromycin Approved Phase 4 81103-11-9 84029
6
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
7
Metronidazole Approved Phase 4 443-48-1 4173
8
Prucalopride Approved Phase 4 179474-81-8
9
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
10
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
11
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
12
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560 441411
13
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
14
Bisacodyl Approved Phase 4 603-50-9
15
Glucagon Approved Phase 4 16941-32-5
16
Cinacalcet Approved Phase 4 226256-56-0 156419
17
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
18
Liraglutide Approved Phase 4 204656-20-2 44147092
19
Zinc Approved, Investigational Phase 4 7440-66-6 32051
20
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
21
Salmon calcitonin Approved, Investigational Phase 4 47931-85-1 16129616
22
Quinagolide Approved, Investigational Phase 4 87056-78-8, 97805-50-0 105105
23
Cefazolin Approved Phase 4 25953-19-9 656510 33255
24
Cefdinir Approved Phase 4 91832-40-5 6915944
25
Cefuroxime Approved Phase 4 55268-75-2 5479529 5361202
26
Sulfamethoxazole Approved Phase 4 723-46-6 5329
27
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
28
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
29
Nitric Oxide Approved Phase 4 10102-43-9 145068
30
Pasireotide Approved Phase 4 396091-73-9 9941444
31
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
32
Cabergoline Approved Phase 4 81409-90-7 54746
33
Sodium sulfate Approved, Vet_approved Phase 4 7757-82-6
34
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
35
Acetaminophen Approved Phase 4 103-90-2 1983
36
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
37
Codeine Approved, Illicit Phase 4 76-57-3 5284371
38
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
39
Sodium citrate Approved, Investigational Phase 4 68-04-2
40
Magnesium citrate Approved Phase 4 3344-18-1
41
lanreotide Approved Phase 4 108736-35-2
42
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
43
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
44
Calcitonin gene-related peptide Investigational Phase 4 83652-28-2
45 Anti-Bacterial Agents Phase 4
46 Cholinergic Agents Phase 4
47 Muscarinic Antagonists Phase 4
48 Cholinergic Antagonists Phase 4
49 Anticonvulsants Phase 4
50 Bromides Phase 4

Interventional clinical trials:

(show top 50) (show all 940)
# Name Status NCT ID Phase Drugs
1 Effects of Ilaprazole 20mg on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone Endoscopic Submucosal Dissection(ESD) for Gastric Adenoma or Early Gastric Cancer. Unknown status NCT02638584 Phase 4 Ilaprazole;Rabeprazole
2 Efficacy and Cost-effectiveness of Colonoscopy vs. Combined Fecal Immunochemical Test-Sigmoidoscopy for the Detection of Advanced Colorectal Neoplasia (eCOLO-FITS): A Randomized Multicenter Trial Unknown status NCT01767870 Phase 4
3 Premedication Dyclonine Improves Visibility During Bowel Cleansing for Colonoscopy Unknown status NCT03352700 Phase 4 3L PEG;3L PEG+Dyclonine Hydrochloride Mucilage
4 Impact of Reinforced Education by Wechat and Short Message Service on the Quality of Bowel Preparation Unknown status NCT02832869 Phase 4
5 Does Hyoscine N-butylbromide Administered During Colonoscopy Increase the Polyp Detection Rate? a Randomized, Single Center, Double Blind, Placebo-controlled Study Unknown status NCT01609855 Phase 4 Hyoscine Butyl Bromide 20mg/2 ml i.v.;Saline 2 ml i.v.
6 Comparison of the Efficacy and Tolerability Between 3-L and 4-L Polyethylene Glycol in Bowel Preparation Unknown status NCT03356015 Phase 4 4L Polyethylene Glycol;3L Polyethylene Glycol
7 Influence of Synacthen Infusion on the Results of Adrenal Venous Sampling in Patient With Primary Aldosteronism Unknown status NCT02127840 Phase 4 Synacthen infusion during adrenal venous sampling
8 Prophylactic Pancreatic Duct Stent Placement After Endoscopic Snare Papillectomy of Duodenal Major Papillary Tumors; Prospective, Randomized, Controlled Study Unknown status NCT01737463 Phase 4
9 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
10 Long-term (up to 3 Years) Clinical and Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues: Open-labeled, Prospective, Parallel Group Study Unknown status NCT02427295 Phase 4 Sandostatin (Octreotide Acetate)
11 Efficacy of Prucalopride Plus Polyethylene Glycol in Bowel Preparation for Colonoscopy Unknown status NCT02781493 Phase 4 2 mg Prucalopride plus 2 L Polyethylene Glycol regimen;2 mg Placebo plus 2 L Polyethylene Glycol regimen
12 The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism Unknown status NCT00451672 Phase 4 bromocriptine
13 Helicobacter Pylori Eradication Rates of Concomitant Therapy and Tailored Therapy Based on 23S Ribosomal RNA Point Mutations Associated With Clarithromycin Resistance: A Multicenter Prospective Randomized Study Unknown status NCT03130452 Phase 4 Lansoprazole 30mg;Amoxicillin 1.0g Tab;Clarithromycin 500mg;Metronidazole 500 mg
14 Optimal Bowel Preparation Regimen for Patients With With a History of Colorectal Resection Before Colonoscopy Unknown status NCT02761317 Phase 4 standard preparation (2L PEG-ELS);low-volume preparation (10 mg bisacodyl plus 2L PEG-ELS);high-volume preparation (4L PEG-ELS)
15 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-protocol is Identical to Study No. 0519-10-TLV- Minors' Adjusted Version Unknown status NCT02354560 Phase 4 Erythromycin
16 Erythromycin as a Novel Therapy Against Familial Adenomatous Polyposis and Sporadic Colorectal Cancer by APC Nonsense Mutation Readthrough. Unknown status NCT02175914 Phase 4 Erythromycin
17 Clinical Effectiveness of Serum Chromogranin A (CgA) Levels on Diagnostic Relevance, Response After Surgical Resection and Recurrence of Pancreatic Endocrine Tumors (PET) Unknown status NCT02759718 Phase 4
18 Ejaculatory Sparing vs. Non-ejaculatory Sparing GreenLightTM Laser Photoselective Vaporization of the Prostate (PVP): A Randomized Double Blind Sexual and Urodynamic Assessment Unknown status NCT02749604 Phase 4
19 Can Involvement of Endoscopy Nurse Participation Increase Adenoma Detection Rate During Screening Colonoscopy?:A Prospective Multicenter Randomized Trial Completed NCT01124266 Phase 4
20 A SINGLE-ARM OPEN-LABEL INTERNATIONAL MULTI-CENTER STUDY OF THE EFFICACY AND SAFETY OF SUNITINIB MALATE (SU011248, SUTENT (REGISTERED)) IN PATIENTS WITH PROGRESSIVE ADVANCED METASTATIC WELL-DIFFERENTIATED UNRESECTABLE PANCREATIC NEUROENDOCRINE TUMORS Completed NCT01525550 Phase 4 sunitinib
21 The Effect Of Adding High Dose Simethicone To A Standard Polyethylene Glycol Preparation On Adenoma Detection Rate During Screening Colonoscopy: A Randomized Controlled Pilot Trial Completed NCT03119168 Phase 4 Simethicone Solution
22 A Multi-centre, Randomised, Investigator-blinded Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate) Completed NCT01689792 Phase 4 MOVIPREP;CitraFleet
23 Comparative Efficacy of Water & Indigo Carmine vs Water or Air Method Completed NCT01607255 Phase 4 Indigo carmine
24 A Multicenter, Single Arm, Proof of Concept Study to Investigate the Efficacy of an 8 Month Combination Therapy of Octreotide and Cabergoline in Acromegalic Patients Only Partially Responsive to Somatostatin Analog Monotherapy Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
25 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4 Octreotide
26 Effect of Gum Chewing on Bowel Cleansing Before Colonoscopy: A Prospective Randomized Study Completed NCT02507037 Phase 4 polyethylene glycol
27 Role of Glucagon in Outpatient Colonoscopy? A Prospective Double-Blind Randomized Controlled Trial Completed NCT02078726 Phase 4 Glucagon;Placebo
28 Prospective, Multicenter Study for the Evaluation of Safety and Performance of the Interscope EndoRotor Endoscopic Mucosal Resection System for the Removal of Alimentary Tract Mucosa in the Colon Completed NCT04203667 Phase 4
29 Does Surgical Debulking Of Pituitary Adenomas Improve Responsiveness To Octreotide LAR In The Treatment Of Acromegaly: An Investigator-Initiated Study Completed NCT01371643 Phase 4 Octreotide LAR
30 Green Light Laser (XPS) Photoselective Vaporization of the Prostate (PVP) Versus Bipolar Transurethral Vaporization (B.TUVP) of the Prostate for Treatment of Small to Moderate Sized Benign Prostate Hyperplasia: A Randomized Study Completed NCT02283684 Phase 4
31 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment: Correlation With Disease Activity, Insulin Sensitivity and Secretion Parameters Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
32 A Prospective Randomised Controlled Trial Comparing Cap-Assisted Colonoscopy Versus Standard Colonoscopy Completed NCT00930462 Phase 4
33 Evaluation of the Effects of Monopolar Transurethral Resection Versus Bipolar Transurethral Resection and Holmium Laser Enucleation of the Prostate on Urinary and Sexual Function; a Prospective Comparative Study. Completed NCT01810068 Phase 4
34 Efficacy of a Calcimimetic (Cinacalcet) in the Long Term Control of Patients With Primary Hyperparathyroidism Completed NCT02417389 Phase 4 cinacalcet;Alendronate
35 Tailored Bowel Preparation According to Bristol Stool Form Scale: a Prospective, Randomized, Controlled, Investigator-blinded, Multicenter Study Completed NCT02415569 Phase 4 Standard Bowel Prep (2L PEG-ELP);2L PEG-ELP and 10mg bisacodyl;Standard Bowel Prep (2L PEG-ELP)
36 Randomized Study Comparing Holmium Laser Enucleation of the Prostate (HOLEP) Versus Greenlight (XPS) Laser Photoselective Vapo-Enucleation of Prostate(PVEP) in the Management of Infravesical Obstruction Secondary to BPH Completed NCT01494337 Phase 4
37 Effects of Preoperative Administration of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection(EMR): Prospective, Randomized, Placebo-controlled, Comparative Study Completed NCT00844675 Phase 4 rabeprazole;placebo
38 A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
39 Improving the Sensitivity of Sestamibi SPECT-CT Parathyroid Scan With Calcitonin Pre-treatment for Primary Hyperparathyroidism Recruiting NCT03935984 Phase 4 Calcitonin
40 PRolaCT - Three Multicenter Prolactinoma Randomized Clinical Trials Recruiting NCT04107480 Phase 4 Dopamine Agonists
41 A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Impact of Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
42 Comparative Effectiveness of Split-Dose Colonoscopy Bowel Preparation Regimens Recruiting NCT03298945 Phase 4 Miralax-Gatorade Prep;Golytely
43 The Role of Aldosterone on Sympathetic Nerve Activity and Insulin Sensitivity Recruiting NCT02102243 Phase 4 DEFINITY® infusion;Human Recombinant Regular Insulin infusion;Dextrose infusion
44 Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding Active, not recruiting NCT02032784 Phase 4 octreotide
45 Phase IV, Open-label, Multi-center, Single-arm Study of the Safety and Efficacy of Everolimus (Afinitor) in Adult Patients With Local Advanced or Metastatic, Well Differentiated Progressive Pancreatic Neuroendocrine Tumors (pNET) in China. Active, not recruiting NCT02842749 Phase 4 everolimus
46 A Multicentre Randomized Parallel Group Phase IV Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of PLENVU® Versus SELG-ESSE® Using a 2-Day Split Dosing Regimen. Active, not recruiting NCT03742232 Phase 4 PEG3350;Macrogol 4000
47 Minimizing Narcotic Analgesics After Thyroid or Parathyroid Surgery Active, not recruiting NCT03469310 Phase 4 Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol
48 An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment Active, not recruiting NCT01794793 Phase 4 Pasireotide;Cabergoline;Pasireotide
49 Eficacia y Tolerabilidad de Dos Productos de Volumen Reducido Para la Colonoscopia de Cribado: Ensayo Comparativo Paralelo Aleatorizado Not yet recruiting NCT04297423 Phase 4 Plenvu
50 Transanal Endoscopic Microsurgery Versus Endoscopic Submucosal Dissection For Large Rectal Adenomas Suspended NCT01023984 Phase 4

Search NIH Clinical Center for Papillary Adenoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Octreotide
Octreotide Acetate

Cochrane evidence based reviews: adenoma

Genetic Tests for Papillary Adenoma

Anatomical Context for Papillary Adenoma

MalaCards organs/tissues related to Papillary Adenoma:

40
Colon, Pituitary, Testes, Prostate, Thyroid, Liver, Pancreas

Publications for Papillary Adenoma

Articles related to Papillary Adenoma:

(show top 50) (show all 304)
# Title Authors PMID Year
1
Pulmonary peripheral glandular papilloma and mixed squamous cell and glandular papilloma frequently harbour the BRAF V600E mutation. 61
32096885 2020
2
Alterations of the bile microbiome in primary sclerosing cholangitis. 61
31243055 2020
3
Renal cell tumors with an entrapped papillary component: a collision with predilection for oncocytic tumors. 61
31444626 2020
4
Thyroid-related hormones as potential markers of hypoxia/ischemia. 61
32146707 2020
5
Diagnosis and management of glandular papilloma of lung: A case report. 61
32258080 2020
6
[Successful intraductal radiofrequency ablation of residual adenoma tissue following endoscopic papillectomy]. 61
32198738 2020
7
Solitary glandular papilloma of the lung with molecular analysis: A case report and literature review. 61
32139260 2020
8
Adenocarcinoma-Papillary Cystic Pattern Arising in a Mixed Squamous and Glandular Papilloma of the Lung. 61
32098550 2020
9
Mixed squamous cell and glandular papilloma of the lung-A case report and literature review in Japan. 61
32114350 2020
10
Risk factors for delayed hemorrhage after endoscopic sphincterotomy. 61
31983673 2020
11
Pulmonary papillary adenoma with malignant transformation: report of one case and review of the literature. 61
32355529 2020
12
Validation of Region of Interest Measurements for the Objective Assessment of Post-Contrast Enhancement of Renal Lesions on MRI. 61
31365281 2019
13
Integrated Molecular Analysis of Papillary Renal Cell Carcinoma and Precursor Lesions Unfolds Evolutionary Process from Kidney Progenitor-Like Cells. 61
31381885 2019
14
[Anatomoclinical and immunohistochemical study of hidradenoma papilliferum, a tumor deriving from anogenital mammary-like glands]. 61
31285043 2019
15
[Surgery of Papillary Adenoma;Report of a Case]. 61
31506417 2019
16
Rare Huge Tubular Papillary Adenoma on the Buttock Demonstrated by Magnetic Resonance Imaging (MRI). 61
31406100 2019
17
Allosteric and ATP-Competitive Inhibitors of mTOR Effectively Suppress Tumor Progression-Associated Epithelial-Mesenchymal Transition in the Kidneys of Tsc2+/- Mice. 61
31207499 2019
18
Malignant rhabdoid tumor of the musk gland and systemic T-cell lymphoma in a masked palm civet (Paguma larvata). 61
31092741 2019
19
A case of intraductal papillary neoplasm of the bile duct that developed 38 years after choledochoduodenostomy with invasive adenocarcinoma and lymph node metastasis. 61
31175474 2019
20
Surgical Resection of Endobronchial Glandular Papilloma. 61
30309633 2019
21
[Clinicopathological analysis of pulmonary mixed squamous cell and glandular papilloma]. 61
30955271 2019
22
Endoscopic Papillectomy for Major and Minor Papillary Adenoma in Familial Adenomatous Polyposis. 61
31620503 2019
23
Papillary Adenomas and Other Small Epithelial Tumors in the Kidney: An Autopsy Study. 61
30418186 2019
24
Mixed squamous cell and glandular papilloma of the lung: A case report of a novel mutation in the BRAF gene and coexistent HPV infection, possible relationship to ciliated muconodular papillary tumor. 61
30664316 2019
25
A 17-year-old woman with a solitary, mixed squamous cell and glandular papilloma of the bronchus. 61
30519472 2019
26
Histologic characteristics and prognosis of lung mixed squamous cell and glandular papilloma: six case reports. 61
31934202 2019
27
Coexistence of glandular papilloma and sclerosing pneumocytoma in the bronchiole. 61
29696743 2018
28
AMACR Positive Papillary Renal Adenomatosis and Multifocal Papillary Carcinoma in End Stage Renal Disease. 61
29887709 2018
29
MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma. 61
29549624 2018
30
A unique case of a huge mixed squamous cell and glandular papilloma of non-endobronchial origin with a peripheral growth. 61
29977775 2018
31
Tubulopapillary Cystic Adenoma With Apocrine Differentiation: A Unifying Concept for Syringocystadenoma Papilliferum, Apocrine Gland Cyst, and Tubular Papillary Adenoma. 61
28033156 2017
32
Genitourinary Malignancies in Transplant or Dialysis Patients: The Frequency of Two Newly Described 2016 World Health Organization Histopathologic Types. 61
28923625 2017
33
Pulmonary Papillary Adenoma: Report of Two Cases. 61
29017679 2017
34
GLUT-1 expression of pulmonary mixed squamous cell and glandular papilloma may be associated with high SUVmax on fluorodeoxyglucose-positron emission tomography. 61
28590021 2017
35
Expression of p16Ink4a in mixed squamous cell and glandular papilloma of the lung. 61
28470939 2017
36
Gallbladder papillary neoplasms share pathological features with intraductal papillary neoplasm of the bile duct. 61
28415560 2017
37
Expression of erythropoietin and neuroendocrine markers in clear cell renal cell carcinoma. 61
28233444 2017
38
Long-term observation and treatment of a widespread intraductal papillary neoplasm of the bile duct extending from the intrapancreatic bile duct to the bilateral intrahepatic bile duct: A case report. 61
28763696 2017
39
A Case of Syringocystadenoma Papilliferum with Tubular Papillary Adenoma of the Chest. 61
28502963 2017
40
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. 61
26935559 2016
41
Cytomorphologic findings and differential diagnosis of pulmonary papillary adenoma: A case report and literature review. 61
27040894 2016
42
Mixed squamous cell and glandular papilloma of the lung resembling early adenocarcinoma: A case report. 61
27141302 2016
43
Papillary adenoma arising from an extensive biliary low-grade intraepithelial neoplasia. 61
26477935 2016
44
Papillary adenoma of the common bile duct: Infrequent pathology, novel endoscopic resolution, rare complication. A case report. 61
26993161 2016
45
Ciliated muconodular papillary tumor: a solitary peripheral lung nodule in a teenage girl. 61
26826405 2016
46
Complex APC germline mutation associated metaplasia and intraepithelial neoplasia (CAM-IEN) of the gallbladder. 61
26643927 2016
47
GATA3 Expression in Normal Skin and in Benign and Malignant Epidermal and Cutaneous Adnexal Neoplasms. 61
26595821 2015
48
[Mixed squamous cell and glandular papilloma: a report of 4 cases and review of literature]. 61
26888391 2015
49
A rare cause of chronic cough: solitary glandular papilloma of the lung. 61
24796508 2015
50
Pulmonary papillary adenoma presenting in central portion: a case report. 61
26474555 2015

Variations for Papillary Adenoma

Expression for Papillary Adenoma

Search GEO for disease gene expression data for Papillary Adenoma.

Pathways for Papillary Adenoma

Pathways related to Papillary Adenoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.16 VIM TP53 KRAS HRAS
2
Show member pathways
11.91 TP53 TFE3 PRCC KRAS HRAS
3 11.69 TP53 KRAS HRAS
4 11.65 TP53 KRAS HRAS
5
Show member pathways
11.61 VIM KRT7 KRT5
6 11.3 TP53 KRAS HRAS
7 11.18 TP53 KRAS HRAS
8 10.76 TP53 TFE3 KRAS HRAS
9 10.44 KRAS HRAS

GO Terms for Papillary Adenoma

Cellular components related to Papillary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear matrix GO:0016363 9.33 VIM TP53 OGG1
2 multivesicular body lumen GO:0097486 8.96 SFTPC NAPSA
3 alveolar lamellar body GO:0097208 8.62 SFTPC NAPSA

Biological processes related to Papillary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.55 VIM TP53 NKX2-1 KRAS HRAS
2 Ras protein signal transduction GO:0007265 9.43 TP53 KRAS HRAS
3 response to isolation stress GO:0035900 8.96 KRAS HRAS
4 regulation of long-term neuronal synaptic plasticity GO:0048169 8.8 SYP KRAS HRAS

Sources for Papillary Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....